Cost comparison of antibacterial therapies for serious infections: A New Zealand 3-hospital study

PharmacoEconomics

Volumn 16, Issue 2, 1999, Pages 183-192

  Scott, W Guy ^a,b,f   Scott, Helen M ^a   Henderson, Seton ^c   Inder, Alison ^c   Sanders, Joanne ^c   Spearing, Ruth ^c   McArthur, Colin ^d   Judson, James ^d   Baker, Bartrum ^e   Hicks, Peter ^e   Cotterell, Philippa ^e  

^a W Guy Scott and Associates Limited   (New Zealand)

^b MASSEY UNIVERSITY   (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e PALMERSTON NORTH HOSPITAL   (New Zealand)

^f NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; ANTIINFECTIVE AGENT; CEFUROXIME; CILASTATIN; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; INFUSION FLUID; METRONIDAZOLE; PIPERACILLIN; TAZOBACTAM;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; COST OF ILLNESS; DRUG COST; DRUG MONITORING; DRUG UTILIZATION; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; NEW ZEALAND; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; HEALTH CARE COSTS; HUMANS; INFECTION; NEW ZEALAND;

EID: 0032820734     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916020-00007     Document Type: Article

References (14)

1. Atkinson HC, Chambers ST, McGinlay AM. Antibiotic therapy costs. N Z Med J 1989; 102: 409-11
2. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed., New York and Toronto: Oxford University Press, 1997
3. Luce BR, Manning WG, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness analysis in health and medicine. 1st ed. Oxford: Oxford University press. 1996: 176-213
4. Kerr JR, Barr JG, Smyth ETM, et al. Technique for calculation of the true costs of antibiotic therapy. Eur J Clin Microbiol Infect Dis 1992; 11 (9): 823-7
5. Davis R, Bryson HM. Ceftriaxone: a pharmacoeconomic evaluation of its use in the treatment of serious infections. Pharmacoeconomics 1994; 6 (3): 249-69
6. Norton A. Nursing pay rates continue to widen. Nurs N Z 1997; 3 (8): 12
7. Statistics New Zealand. Personal computer information network for official statistics: a computerised database of official statistics for New Zealand and programme for manipulation and analysis of statistical series (PC INFOS). Wellington: Statistics New Zealand, 1996
8. Malek M, Lynch W, Wells N, et al. Antimicrobial practice: a comparison of the costs of ceftazidime therapy and gentamicin combinations in three UK hospitals. J Antimicrob Chemother 1992; 29: 207-17
9. Norrby SR. Pharmacoeconomic studies on antibiotics: current controversies. Pharmacoeconomics 1994; 5 (4): 274-7
10. Beringer PM, Wong-Beringer A, Rho JP. Economic aspects of antibacterial adverse effects. Pharmacoeconomics 1998; 13 (1): 35-49
11. Birmingham MC, Hassett JM, Schentag JJ, et al. Assessing antibacterial pharmacoeconomics in the intensive care unit. Pharmacoeconomics 1997; 12 (6): 637-47
12. Norrby SR, Eriksson M, Ottosson E. Imipenem-cilastatin versus gentamicin-clindamycin: a cost effectiveness study. Scand J Infect Dis 1986; 18: 371-4
13. Eisenberg JM, Koffer H, Glick HA, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900-9
14. Ministry of Health. Purchasing for your health 1996/97: a performance report on the fourth year of the Regional Health Authorities (appendix eleven: RHA price database 1996/97, average base contract prices paid for AN-DRGs, version 3.1, by the RHAs in 1996/97). Wellington: Ministry of Health, 1998